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Introduction {#sec1}
============

Obesity is becoming a global pandemic as a result of sustained energy intake exceeding energy expenditure under a modern lifestyle. The discovery that the brown and beige adipose tissues can burn energy to heat instead of energy storing highlights pharmacological activation of brown adipose tissue or induction of beige adipose tissue as promising strategies to target obesity ([@bib15]; [@bib14]; [@bib2]). The energy burning properties of brown or beige adipocytes lies mostly in the expression of UCP1 (uncoupling protein 1), a protein that is highly expressed in brown and beige adipocytes and localized on the inner mitochondrial membrane. When activated, UCP1 uncouples oxidative respiration from ATP synthesis, resulting in heat generation ([@bib9]). Therefore, UCP1 serves as a promising molecular target to thermogenesis enhancement and obesity treatment. Although plenty of compounds have been reported to increase UCP1 expression in adipocytes ([@bib1]; [@bib33]; [@bib37]; [@bib18]; [@bib10]), safe and effective compounds that can be used clinically are still lacking.

We have previously developed a cellular screening platform with the *Ucp1-2A-GFP* reporter cell lines, which allows high-throughput screenings using a fluorescence signal as readout ([@bib25]). Using this reporter line, we have identified a group of drugs that can upregulate UCP1 expression in brown adipocytes and reported sutent as an effective modulator of UCP1 expression in brown adipose tissue ([@bib25]). Sutent belongs to the tyrosine kinase (RTK) inhibitor family and has been used clinically to treat certain kidney, pancreatic, and gastrointestinal cancers. Although sutent treatment did not cause obvious adverse effect in our study in animals, side effects observed in patients renders it impossible for immediate repurposing to treat obesity.

It is very interesting that Glyburide, one of the drugs used in lowering blood glucose, has shown a strong effect in upregulating UCP1 in brown adipocytes in our screening. Glyburide is a sulfonylurea drug, also known as glibenclamide in Europe, which can directly bind to and block the SUR1 subunits of ATP-dependent potassium channels (K~ATP~) and consequently increase insulin secretion from the pancreatic β cells. Glyburide has been approved to treat type 2 diabetes clinically ([@bib20]), which has also been repurposed for the treatment of acute central nervous system injury recently ([@bib17]).

Previous studies have indicated an interesting aspect of ions channels and the electrophysiological modulation in the regulation of thermogenesis activity in brown and beige adipocytes. For example, KCNK3, a two-pore-domain potassium channel, which promotes outward K^+^ current and limits Ca^2+^ influx, has been shown to affect thermogenesis in brown and beige adipocytes. KCNK3 is highly expressed in brown and beige adipose and is directly regulated by PRDM16. KCNK3 impairs thermogenesis via antagonizing NE-induced membrane depolarization and Ca^2+^ influx to decrease cAMP production ([@bib5]; [@bib24]). TRPV2, a Ca^2+^-permeable non-selective cation channel, was also reported to play vital roles in brown adipose tissue ([@bib31]). Lack of TRPV2 impaired thermogenesis in mouse brown adipose tissue. It is still unclear how TRPV2 activation modulates thermogenesis; however, the induction of thermogenic genes in response to β3-adrenergic receptor stimulation was decreased in TRPV2KO brown adipocytes and suppressed by reduced intracellular Ca^2+^ concentrations in wild-type brown adipocytes.

Combining the previous strong indication of glyburide in upregulating UCP1 in brown adipocytes and the interest whether the effect of glyburide is through K~ATP~ channel inhibiting, we decided to focus on the functional study of glyburide in adipocytes and to explore the underlying mechanism.

Results {#sec2}
=======

Glyburide Enhanced UCP1 Expression in Adipocytes *In Vitro* {#sec2.1}
-----------------------------------------------------------

Our previous screening suggested strong upregulating effect of glyburide in UCP1 expression in brown adipocytes. We first validated the effect of glyburide in *in vitro* cultured brown adipocytes. Initially, mature brown adipocytes were treated with 10 μM glyburide at day 8 after the maintenance stage for 1 day ([Figure 1](#fig1){ref-type="fig"}A). The lipid content was not changed after glyburide treatment, indicating glyburide had no effect on adipocyte differentiation ([Figure 1](#fig1){ref-type="fig"}B). Consistent with the high-throughput screening results, glyburide treatment significantly increased UCP1 expression in brown adipocytes, at both the mRNA level and the protein level, compared with cells treated with DMSO ([Figures 1](#fig1){ref-type="fig"}C and 1D). Glyburide treatment also stimulated expression of other thermogenic or brown differentiation genes, including *Cidea*, *Pgc1a*, *Ppara*, and *Prdm16* ([Figure 1](#fig1){ref-type="fig"}D). To know whether the glyburide effect is dependent on treatment time point, we then treated cells with glyburide for 3 days at the maintenance stage or 8 days along the whole differentiation process ([Figures S1](#mmc1){ref-type="supplementary-material"}A and S1F). Under these two conditions, cells treated with glyburide both displayed increased UCP1 expression ([Figures S1](#mmc1){ref-type="supplementary-material"}B--S1D and S1G--S1I) and enhanced expression of other thermogenic or brown differentiation genes ([Figures S1](#mmc1){ref-type="supplementary-material"}C and S1H), although with no significant difference as compared with 1-day treatment at day 8 ([Figures 1](#fig1){ref-type="fig"}C and 1D) and with no significant change on adipocyte differentiation either ([Figures S1](#mmc1){ref-type="supplementary-material"}E and S1J). Additionally, UCP1 expression was also significantly increased in day 8 brown adipocytes after glyburide treatment for as short as 4 h, indicating that glyburide stimulates UCP1 expression in a very short time in mature brown adipocytes ([Figures S1](#mmc1){ref-type="supplementary-material"}K and S1L).Figure 1Glyburide Promoted UCP1 Expression in Both Brown and White Adipocytes(A) Schematic view of the brown adipocyte differentiation procedure and compound treatment protocol. Cells were treated with 10 μM glyburide or DMSO for 1 day after 7 days\' differentiation and collected at day 8 for analysis.(B) Assessment of lipid accumulation (evaluated by Oil Red O staining) in glyburide or DMSO-treated *Ucp1-2A-GFP* brown adipocytes. Scale bar, 200 μm.(C) Western blot analysis of UCP1 protein expression in glyburide or DMSO-treated *Ucp1-2A-GFP* brown adipocytes.(D) mRNA expression analyses of genes in glyburide or DMSO-treated *Ucp1-2A-GFP* brown adipocytes. n = 4.(E) Gene Ontology analyses of regulated genes in brown adipocytes after glyburide treatment identified by RNA-seq.(F) Schematic view of the white adipocyte differentiation procedure and compound treatment protocol. Cells were treated with 10 μM glyburide or DMSO for 4 days after 6 days\' differentiation and collected at day 10 for analysis.(G) Assessment of lipid accumulation (evaluated by Oil Red O staining) in glyburide or DMSO-treated *Ucp1-2A-GFP* white adipocytes. Scale bar, 200 μm.(H) Western blot analysis of UCP1 protein expression in glyburide or DMSO-treated *Ucp1-2A-GFP* white adipocytes.(I) mRNA expression analyses of genes in glyburide or DMSO-treated *Ucp1-2A-GFP* white adipocytes. n = 3.(J) Gene Ontology analyses of regulated genes in white adipocytes after glyburide treatment identified by RNA-seq.(K) Venn analysis of upregulated genes from brown and white adipocytes after glyburide treatment.(L) Heatmap depicting upregulated genes related to lipid metabolism in brown and white adipocytes after glyburide treatment.Bars show mean ± SEM. p Values are shown for indicated comparisons by the Student\'s t test. ∗p \< 0.05, ∗∗p \< 0.01. See also [Figures S1](#mmc1){ref-type="supplementary-material"} and [S2](#mmc1){ref-type="supplementary-material"}.

We next tested the effect of glyburide in cultured white adipocytes. Mature white adipocytes were treated with glyburide for 4 days ([Figure 1](#fig1){ref-type="fig"}F), and the lipid accumulation was not changed after glyburide treatment ([Figure 1](#fig1){ref-type="fig"}G). We noticed significant increase in UCP1 expression upon glyburide treatment at both the mRNA and protein levels ([Figures 1](#fig1){ref-type="fig"}H and 1I). We also observed increased expression of other thermogenic genes, including *Cidea* and *Pgc1a*, indicating the induction of a browning process in white adipocytes ([Figure 1](#fig1){ref-type="fig"}I). Moreover, glyburide effect was also tested after treatment in the whole white adipocyte differentiation process. Cells were treated with glyburide for 8 days during the whole differentiation process for 8 days ([Figure S2](#mmc1){ref-type="supplementary-material"}A). Results demonstrated that glyburide treatment significantly improved UCP1 expression ([Figures S2](#mmc1){ref-type="supplementary-material"}B--S2D), and with a stronger UCP1 induction effect after longer time treatment ([Figure S2](#mmc1){ref-type="supplementary-material"}D), with no significant change on adipocyte differentiation ([Figure S2](#mmc1){ref-type="supplementary-material"}E).

To get a better understanding of glyburide effect, we next performed RNA sequencing (RNA-seq) for glyburide or DMSO-treated brown and white adipocytes. Gene ontology (GO) analysis revealed that glyburide treatment in brown adipocytes led to significant upregulation of in total 505 genes using a cutoff of p ≤ 0.05, which were enriched for lipid metabolic process, fat cell differentiation, and thermogenesis ([Figure 1](#fig1){ref-type="fig"}E). A total of 404 genes were upregulated in white adipocytes after glyburide treatment, which were also significantly enriched in lipid metabolic process, brown fat differentiation, oxidation reduction process, and others ([Figure 1](#fig1){ref-type="fig"}J). Among these upregulated genes, 100 genes were common genes regulated in both brown and white adipocytes after glyburide treatment ([Figure 1](#fig1){ref-type="fig"}K), including important regulators in lipid metabolism, such as *Fgf21*, *Elovl3*, *Ppara*, and *Scd3* ([Figure 1](#fig1){ref-type="fig"}L). Altogether, these data demonstrated that glyburide treatment promoted UCP1 and thermogenesis gene expression in both brown and white adipocytes.

Glyburide Enhanced UCP1 Expression in Adipose Tissues *In Vivo* {#sec2.2}
---------------------------------------------------------------

We next investigated the effect of glyburide treatment *in vivo*. Mice were fed with high-fat diet (HFD) and treated with glyburide at the dose of 2 mg/kg/day through oral administration for 11 week ([Figure 2](#fig2){ref-type="fig"}A). Glyburide treatment caused significant body weight loss (−9% after 11-week treatment) ([Figure 2](#fig2){ref-type="fig"}B), whereas no significant change was observed in food intake ([Figure S3](#mmc1){ref-type="supplementary-material"}A). Serum analyses showed a clear reduction of total triglyceride (TG) (−35.92%), with no significant change of total cholesterol (TC) or free fatty acid contents in mice treated with glyburide ([Figures 2](#fig2){ref-type="fig"}C and [S3](#mmc1){ref-type="supplementary-material"}B). Consistent with body weight loss, organ weights of BAT (brown adipose tissue, −9.76%), eWAT (epididymal white adipose tissue, −32.97%), and iWAT (inguinal white adipose tissue, −30.6%) were reduced significantly in glyburide-treated mice ([Figure 2](#fig2){ref-type="fig"}D). The reduction in body and organ weights were mostly caused by decrease in fat mass (−29.52%) as revealed by the NMR analysis ([Figure 2](#fig2){ref-type="fig"}E). Furthermore, histological analyses of adipose tissues displayed significantly reduced adipocyte size in BAT, eWAT, and iWAT ([Figure 2](#fig2){ref-type="fig"}F), although no significant change was observed in liver triglyceride or liver cholesterol content ([Figure S3](#mmc1){ref-type="supplementary-material"}C). Consistent with the results in cultured cells, glyburide treatment resulted in significant increase of UCP1 expression in brown adipose tissue ([Figure 2](#fig2){ref-type="fig"}G). Metabolic analysis displayed a minor increase in O~2~ consumption after glyburide treatment, if calculated with normalization to body weight ([Figures 2](#fig2){ref-type="fig"}H and 2I); however, no significant change in net O~2~ consumption was observed ([Figures S3](#mmc1){ref-type="supplementary-material"}G and S3H). In the meantime, there was minimal change in physical activity ([Figure S3](#mmc1){ref-type="supplementary-material"}D). Besides, expression levels of other thermogenic genes, including *Cidea*, *Dio2*, *Pgc1a, Ppara*, and *Prdm16*, in brown adipose tissue were not changed after glyburide treatment ([Figures S3](#mmc1){ref-type="supplementary-material"}E and S3F). Altogether, these results indicated that the phenotypic changes observed in mice after glyburide treatment are at least partly caused by improved UCP1 expression in brown adipose tissue.Figure 2Glyburide Treatment Promoted Weight Loss of Mice under HFD(A) Schematic view of mouse experiments. Mice were administrated 2 mg/kg glyburide or vehicle through daily oral feeding under HFD for 11 weeks.(B) Body weights of mice treated with glyburide or vehicle under HFD (left) and representative image of mouse treated with glyburide or vehicle 11 weeks later (right). n = 12. Scale bar, 1 cm.(C) Serum total triglyceride (TG) and total cholesterol (TC) content of mice measured after 11-week treatment with glyburide or vehicle. n = 12.(D) Weights of different mouse adipose tissues (left) and representative fat images of different mouse adipose tissues (right) after 11-week treatment with glyburide or vehicle. n = 12. Scale bar, 1 cm.(E) Body lean and fat composition of mice determined by NMR after 10-week treatment with glyburide or vehicle. n = 12.(F) Representative HE staining images of BAT, iWAT, and eWAT. Scale bar, 100 μm.(G) Western blot analysis of UCP1 protein expression level in mouse brown adipose tissues.(H) Oxygen consumption measurement of mice in metabolic cages after 11-week treatment with glyburide or vehicle. n = 8.(I) CO~2~ content measurement of mice in metabolic cages after 11-week treatment with glyburide or vehicle. n = 8.Bars show mean ± SEM. p Values are shown for indicated comparisons by the Student\'s t test (B--E and G) or two-way ANOVA (H and I). ∗p \< 0.05, ∗∗p \< 0.01. See also [Figures S3](#mmc1){ref-type="supplementary-material"} and [S4](#mmc1){ref-type="supplementary-material"}.

We also treated mice with a lower dose of 50 μg/kg/day via oral administration, which is more relevant to the therapeutic glyburide doses used clinically ([@bib27]). Low-dose glyburide treatment did not cause significant change in either body weight or body composition in mice under HFD ([Figures S4](#mmc1){ref-type="supplementary-material"}A and S4C). Besides, low-dose glyburide treatment led to no significant change in energy expenditure, as reflected by minimal change of O~2~ consumption and CO~2~ content, with the comparable physical activity ([Figures S4](#mmc1){ref-type="supplementary-material"}E and S4G). Food intake monitoring did not show significant change after glyburide treatment ([Figure S4](#mmc1){ref-type="supplementary-material"}B). Serum analysis indicated no significant change in total cholesterol or in total triglyceride level in mice treated with glyburide under HFD ([Figure S4](#mmc1){ref-type="supplementary-material"}D). Mice were then dissected for further investigation. Overall, there was no significant change in total organ weight or adipocytes sizes in BAT, eWAT, or iWAT ([Figures S4](#mmc1){ref-type="supplementary-material"}F and S4H). We then tested the insulin and blood glucose responses of animals to different doses of glyburide via oral administration. We found that 2 mg/kg glyburide caused a marked increase of insulin release and rapid drop of blood glucose level, whereas 50 μg/kg glyburide had no effect on the insulin and blood glucose contents of mice ([Figures S4](#mmc1){ref-type="supplementary-material"}I and S4J), suggesting different drug sensitivity of glyburide between human beings and mice.

We suspected that the reason we did not observe a significant phenotypic change in animals after low-dose treatment of glyburide is because the drug cannot reach the adipose tissues, especially when delivered via oral administration. We thus next tested the effect of glyburide directly through *in situ* injection to inguinal white adipose depot. CL-316243 injection was used as a positive control. Four days after a single injection, mice were dissected and inguinal adipose tissues were obtained for UCP1 expression analysis ([Figure 3](#fig3){ref-type="fig"}A). Similar to CL-316243 treatment, we observed a remarkable increase in UCP1 expression in inguinal white adipose depot after glyburide treatment ([Figure 3](#fig3){ref-type="fig"}B). HE and UCP1 staining also displayed a clear browning phenomenon in inguinal adipose tissue, as indicated by smaller lipid droplets and enhanced UCP1 expression ([Figure 3](#fig3){ref-type="fig"}C). In consistency with increased UCP1 expression, levels of the OXPHOS proteins were also increased in glyburide-treated white adipose tissues ([Figure 3](#fig3){ref-type="fig"}D). Moreover, glyburide-treated mice displayed higher rectal temperature in the cold challenge experiment ([Figure 3](#fig3){ref-type="fig"}E). These results altogether demonstrated that glyburide treatment promoted white adipose browning *in vivo*.Figure 3Glyburide Treatment Improved UCP1 Expression in Inguinal White Adipose Tissue(A) Schematic view of mouse experiments. Mice were administrated 1 mg/kg glyburide, 1 mg/kg CL-316243, or vehicle through subcutaneous injection. Four days after a single injection, mice were dissected and inguinal white adipose tissues were obtained for further analysis.(B) UCP1 protein expression analyses of inguinal white adipose tissue after compound treatment with as indicated.(C) Representative images of H&E staining and UCP1 staining of inguinal white adipose tissue after glyburide or vehicle treatment. Scale bar, 210 μm.(D) OXPHOS protein expression analyses in inguinal white adipose tissue of mice treated with glyburide or vehicle.(E) Cold challenge experiment with vehicle or glyburide-treated mice. n = 8. Bars show mean ± SEM. p Values are shown for indicated comparisons by the Student\'s t test. ∗p \< 0.05, ∗∗p \< 0.01.

The Effect of Glyburide in UCP1 Upregulation Was K~ATP~ Independent {#sec2.3}
-------------------------------------------------------------------

Glyburide is a second-generation sulfonylurea drug that has been used to treat patients with type 2 diabetes mellitus. It stimulates insulin secretion through the closure of ATP-sensitive potassium channels (K~ATP~) on pancreatic β cells, raising intracellular calcium ion concentration ([@bib13]). The K~ATP~ channel is a heteroctameric complex composed of four inwardly rectifying pore-forming K^+^ channel subunits (Kir6.x; Kir6.1 or Kir6.2) and four regulatory sulfonylurea receptor SUR ATP-binding cassettes subunits (SUR; SUR1 or SUR2) ([@bib23]). Diverse classes of K~ATP~ channels exist, which differ from each other in different tissues and cell types in terms of their nucleotide sensitivities, their biophysical properties, and their sensitivities to pharmacological agents ([@bib11]). In pancreatic β cells Kir6.2/SUR1 are the major subunits expressed, in cardiac myocytes Kir6.2/SUR2A subunits, in smooth muscles SUR2B, whereas in adipose tissue Kir6.1/SUR2B are the major forms ([@bib32]). To directly assess whether K~ATP~ channel is involved in UCP1 upregulation by glyburide, we next knocked out either Kir subunits or SUR subunits of K~ATP~ channels using the CRISPR-Cas technology in adipocytes. We screened individual sgRNAs targeting *Kir6.1*, *Kir6.2*, *Sur1*, as well as *Sur2* genes. All sgRNAs demonstrated high editing activity in brown adipocytes ([Figure 4](#fig4){ref-type="fig"}A). However, we did not observe significant change of UCP1 expression either at the mRNA level or the protein level after depleting two *Kir* genes (*Kir*-sgRNAs: *Kir6.1*-sgRNA and *Kir6.2*-sgRNA) or two *Sur* genes (*Sur*-sgRNAs: *Sur1*-sgRNA and *Sur2*-sgRNA) in brown adipocytes. In the meantime, glyburide treatment still upregulated UCP1 expression in *Kir*-sgRNAs and *Sur*-sgRNAs cells, showing no significant difference in comparison with the effect in control cells ([Figures 4](#fig4){ref-type="fig"}B--4D). These results demonstrated that, although glyburide was supposed to target K~ATP~ channel, it stimulated the expression of UCP1 in adipocytes in a K~ATP~ channel-independent manner. Moreover, Epac2, which is a guanine nucleotide exchange factor for the small guanosine triphosphatase Rap1, was reported to be another direct target of antidiabetic sulfonylurea drugs ([@bib35]). We therefore next tested whether glyburide increases UCP1 expression via targeting Epac2. We screened an sgRNA targeting the second exon of the mouse *Epac2* gene, which showed high editing activity ([Figure S5](#mmc1){ref-type="supplementary-material"}A). However, we did not observe significant increase of UCP1 expression in *Epac2*-KO brown adipocytes, and meanwhile, *Epac2*-KO did not abrogate the effect of glyburide in upregulating UCP1 expression ([Figures S5](#mmc1){ref-type="supplementary-material"}B, S5C, and S5F).Figure 4Glyburide Increased UCP1 Expression Independent of KATP Blockade(A) Schematic view of CRISPR sgRNAs design for indicated genes and genome editing activity of selected sgRNAs as indicated.(B) Western blot analyses of indicated proteins in CRISPR sgRNAs-treated brown adipocytes.(C) *Ucp1* mRNA expression analyses of brown adipocytes treated with CRISPRs and compounds as indicated. n = 3.(D) UCP1 protein expression analyses of brown adipocytes treated with CRISPRs and compounds as indicated.(E) The suggested target(s) and structure information of selected compounds.(F) UCP1 protein expression analyses of brown adipocytes treated with compounds (10 μM) as indicated.(G) *Ucp1* mRNA expression analyses of brown adipocytes treated with compounds (10 μM) as indicated. n = 3.(H) *Ucp1* mRNA expression analyses of brown adipocytes treated with compounds as indicated. n = 3.(I) UCP1 protein expression analyses of white adipocytes treated with compounds as indicated.Bars show mean ± SEM. p Values are shown for indicated comparisons by the Student\'s t test. ∗p \< 0.05, ∗∗p \< 0.01. See also [Figure S5](#mmc1){ref-type="supplementary-material"}.

To further confirm whether the glyburide effect in UCP1 upregulation is K~ATP~ independent or Epac2 independent, we chose another four compounds that can also target K~ATP~ or/and Epac2 ([Figure 4](#fig4){ref-type="fig"}E). However, only glyburide treatment was able to increase UCP1 expression in brown adipocytes, with little effect from other compounds ([Figures 4](#fig4){ref-type="fig"}F and 4G). Furthermore, treatment with a combination of four compounds had no effect in UCP1 expression or the UCP1 upregulation by glyburide ([Figure 4](#fig4){ref-type="fig"}H). Similarly, only glyburide, but none of the other four K~ATP~ inhibitors, was able to increase UCP1 expression in white adipocytes ([Figure 4](#fig4){ref-type="fig"}I). Taken together, these results suggest a unique feature of glyburide that upregulates UCP1 expression, which is K~ATP~ independent and Epac2 independent.

Caveolin was previously reported to be involved in the action of glimepiride, a sulfonylurea drug with very close structure with glyburide. Caveolin was tyrosine phosphorylated in isolated rat adipocytes in response to glimepiride treatment, playing important functions in transmembrane signal transduction ([@bib21]; [@bib22]). Moreover, caveolin-1 (Cav1) is expressed abundantly in adipose tissue and involved in many physiological processes. 3T3-L1 adipocytes overexpressing Cav1 were better differentiated ([@bib3]). We thus next wanted to know whether the effect of glyburide is regulated through Cav1. We also targeted the mouse *Cav1* gene using the CRISPR technology ([Figure S5](#mmc1){ref-type="supplementary-material"}D). However, we did not observe significant change in UCP1 expression in *Cav1*-KO brown adipocytes with or without glyburide treatment ([Figures S5](#mmc1){ref-type="supplementary-material"}E and S5F).

The Effect of Glyburide in UCP1 Upregulation Was Reversed by the Inhibition of the Ca^2+^-Calcineurin-NFAT Signal Pathway {#sec2.4}
-------------------------------------------------------------------------------------------------------------------------

Glyburide can increase cytosolic Ca^2+^ levels in isolated rat adipocytes in a concentrated manner, which was blocked by nitrendipine, an L-type Ca^2+^ channel antagonist ([@bib7], [@bib8]). We thus treated the cells with nitrendipine to test whether the glyburide effect in UCP1 expression was mediated by the increase in intracellular Ca^2+^ levels. We also tested cells with another compound, diazoxide, a potassium channel activator, which was also reported to counteract the effect of glyburide in adipocytes ([@bib30]). Results showed that nitrendipine (Nit) significantly blocked the UCP1 expression induced by glyburide treatment. However, diazoxide (Dia) did not cause significant change in UCP1 expression under basal level or upon glyburide treatment ([Figures 5](#fig5){ref-type="fig"}A and 5B), further confirming that the glyburide effect in UCP1 upregulating is not dependent on potassium channels but may involve regulation from intracellular Ca^2+^ levels. Transient receptor potential vanilloid 2 (TRPV2), a Ca^2+^-permeable non-selective cation channel, was reported to have critical roles in thermogenesis in mouse brown adipose tissue ([@bib31]). We next tested whether the glyburide effect in UCP1 expression was regulated by the TRPV2 channel. We targeted the mouse *Trpv2* gene using the CRISPR technology ([Figure S5](#mmc1){ref-type="supplementary-material"}G). However, we did not observe significant change of UCP1 expression in *Trpv2*-KO brown adipocytes, with or without glyburide treatment ([Figures S5](#mmc1){ref-type="supplementary-material"}H and S5I), suggesting that the glyburide upregulated UCP1 was not through TRPV2.Figure 5Glyburide\'s Effect in UCP1 Upregulation Was Blocked by the Inhibition of Ca^2+^-Calcineurin-NFAT Signal Pathway(A) *Ucp1* mRNA expression analyses of brown adipocytes treated with compounds as indicated. n = 3.(B) UCP1 protein expression analyses of brown adipocytes treated with compounds as indicated.(C) *Ucp1* mRNA expression analyses of brown adipocytes treated with compounds as indicated. n = 3.(D) UCP1 protein expression analyses of brown adipocytes treated with compounds as indicated.(E) *Ucp1* mRNA expression analyses of brown adipocytes treated with compounds as indicated. n = 3.(F) UCP1 protein expression analyses of brown adipocytes treated with compounds as indicated.(G) *Ucp1* mRNA expression analyses of brown adipocytes treated with compounds as indicated. n = 3.(H) UCP1 protein expression analyses of white adipocytes treated with compounds as indicated.(I) The schematic diagram of a working mechanism that glyburide regulates UCP1 expression in adipocytes. Compounds used for treatment were as following: 10 μM Glyburide, 10 μM Diazoxide (Dia), 30 μM Nitrendipine (Nit), 10 μM Cyclosporine A (CsA), 10 μM FK506 (Calcineurin inhibitor), 10 μM VIVIT (NFAT inhibitor). Bars show mean ± SEM. p Values are shown for indicated comparisons by the Student\'s t test. ∗p \< 0.05, ∗∗p \< 0.01.

We next further tested whether glyburide upregulated UCP1 via the Ca^2+^-Calcineurin-NFAT signaling ([@bib6]) by adding the calcineurin inhibitor, cyclosporine A (CsA) or FK506, to glyburide-treated brown adipocytes. Results showed that, similar to nitrendipine, both CsA and FK506 treatment effectively blocked the glyburide effect in UCP1 elevation ([Figures 5](#fig5){ref-type="fig"}C--5F). Moreover, the NFAT inhibitor, VIVIT, which is a cell-permeable peptide inhibitor of nuclear factor of activated T cells (NFAT) that selectively inhibits calcineurin-mediated dephosphorylation of NFAT ([@bib19]), also significantly affected the increase of *Ucp1* expression induced by glyburide treatment ([Figure 5](#fig5){ref-type="fig"}G). Similarly, in white adipocytes, the UCP1 upregulation upon glyburide treatment was also blocked by calcineurin inhibition ([Figure 5](#fig5){ref-type="fig"}H). Altogether, these data suggested that the glyburide effect in UCP1 upregulation could be reversed by the inhibition of Ca^2+^-Calcineurin-NFAT signal pathway ([Figure 5](#fig5){ref-type="fig"}I).

Discussion {#sec3}
==========

Taken together, our study has identified that glyburide, a drug used in clinical treatment of type 2 diabetes, can effectively promote UCP1 expression in brown and white adipocytes, both *in vitro* and *in vivo*. The mechanism of UCP1 upregulation, however, is not mediated by inhibition of the K~ATP~ channel, a well-known target of glyburide. Although the direct target(s) of glyburide in upregulating UCP1 in adipocytes is still unknown, our results suggested the involvement of the Ca^2+^-Calcineurin-NFAT signal pathway in the underlying mechanism.

In our *in vivo* investigations, we found that, when treated with a high dose, glyburide can significantly decrease the gain of whole-body weight due to HFD feeding, and reduce blood triglyceride levels, at least partly due to improved UCP1 expression in brown adipose tissue. However, decreased body weight and blood lipids have not been observed in clinical patients taking glyburide. We suspect that the reason is mainly because the rather low efficiency of glyburide reaching adipose tissues by oral administration. This is similar to animal experiments treated with a low dose of glyburide, in which no obvious phenotypic change was observed. High dose of glyburide will certainly cause severe and life-threatening side effect as low blood glucose; it is therefore unacceptable to increase the dose in patients for the achievement of weight loss effect. As our results demonstrated that *in situ* injection of glyburide directly to the white adipose depots in animals had a strong effect in UCP1 upregulation and thermogenesis enhancement, different approaches for local adipose tissue delivering, for example, local delivery through a microneedle patch ([@bib36]), is essentially the way to go.

The effect of glyburide in adipocytes is not limited to the increase of UCP1 expression, but glyburide imposes a broad effect to the expression of many genes involved in lipid metabolism and thermogenesis, as revealed by the RNA-seq analyses. It is impressive that glyburide treatment led to a significant increase in *Fgf21* expression in both brown and white adipocytes. FGF21 is a protein with multiple metabolic protective reactions, and indeed a bright star on the metabolic disease therapeutic horizon. In fact, several clinical trials are ongoing focusing on FGF21 therapy to metabolic diseases ([@bib29]; [@bib12]; [@bib16]). Our discovery that glyburide can boost the expression of *Fgf21* in adipocytes revealed another beneficial aspect of glyburide treatment, besides the UCP1 upregulation and its long-term safety *in vivo*. However, in a different aspect, to what extent the upregulation of UCP1 explains in the whole phenotypic change upon glyburide treatment would need further investigation, ideally with the *Ucp1* knockout animals.

The direct target(s) of glyburide in adipocyte is intriguing and remains undefined. Glyburide is known to stimulate insulin secretion through closure of the K~ATP~ channel in the pancreatic β cells; however, our results suggest that the K~ATP~ channel is not its target in adipocytes in regulating UCP1 expression. The direct comparison results of glyburide with other K~ATP~ targeting compounds also confirmed the conclusion and suggested different target(s) responsible for the effect of glyburide in UCP1 regulation. Our initial tests with several inhibitors suggest that the Ca^2+^-Calcineurin-NFAT signaling pathway may involve in the effect of glyburide. The Ca^2+^-Calcineurin-NFAT signaling pathway can transmit signals to the nucleus from a wide variety of receptors and is important to developmental events such as axon outgrowth, cardiac morphogenesis, and immune responses ([@bib6]). Previous evidence indicated that the Regulator of Calcineurin 1 (*RCAN1*), a feedback inhibitor of the calcium-activated protein phosphatase calcineurin, was a negative regulator of UCP1 expression in white adipose tissue. Mice lacking *Rcan1* were resistant to diet-induced obesity ([@bib28]). Besides, several reports also pointed out the possible important regulating function of NFAT in adipocyte biology. For example, mice deficient for *Nfatc2* and *Nfatc4* were protected from diet-induced obesity ([@bib34]). And in human, polymorphisms for *NFATc4* gene may confer certain protection or predisposition for the development of new-onset diabetes after kidney allograft transplantation ([@bib4]). Also, genome-wide association studies (GWASs) indicated that the *NFATc1*, *NFATc2*, and *NFATc4* loci are associated with a variety of metabolic traits ([@bib26]). However, to what extent the glyburide effects in adipocytes depend on the Ca^2+^-Calcineurin-NFAT signaling pathway is worth further investigation. Despite these unknowns, the findings that glyburide can increase UCP1 expression in adipocytes both *in vitro* and *in vivo* may shed light on new treatment of obesity and related metabolic diseases.

Limitations of the Study {#sec3.1}
------------------------

In the present study, we showed that glyburide effect in UCP1 upregulation was K~ATP~ independent but may involve the regulation of Ca^2+^-Calcineurin-NFAT signaling pathway. However, further investigations are required to characterize the detailed mechanisms. Additionally, *Ucp1* knockout mice will be helpful to establish the physiological relevance of UCP1 upregulation with the phenotypic change upon glyburide treatment in animals.
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All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.
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